author-photo

Michelle Avellaneda

University of Texas MD Anderson Cancer Center

3

Papers

11

Citations

Citation Trend

Filter By

Papers (2) Sort By

Journal Conference Others

Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial

2020 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

2019 Blood
Show All
- Source
- Cite
- Save
Citations (9)